TACL
Therapeutic Advances in Childhood Leukemia & Lymphoma
Log in
T2020-003 IDEAL 2
Protocol Opened: 2/9/2022
Study Contacts
Study Chair: Dr. Etan Orgel, MD
Study Vice-Chair: Dr. Sarah Tasian, MD
Study Biology Chair: Dr. Steven Mittelman, MD
CURRENT STUDY DOCUMENTS
T2020-003 IDEAL 2 Protocol Amendment #2 Clean Version
T2020-003 IDEAL 2 Protocol Amendment #2 Tracked Version
T2020-003 IDEAL 2 Master Consen
t version 8.20.24
T2020-003 IDEAL 2 Master Assent version 8.20.24
T2020-003 IDEAL 2 Master Addendum to the Consent (same as original)
T2020-003 IDEAL 2 Research Monitoring Plan
T2020-003 IDEAL 2 Amendment #2 Investigator Acknowledgement
T2020-003 IDEAL 2 Investigator Meeting Presentation
Institutional Profile Sheet
Lab Manual
version 2.1
Study Manual
version 10-20-2023
eCRF Completion Guide
v.3.0
IDEAL 2 Delegation of Authority
PREVIOUS STUDY DOCUMENTS
T2020-003 IDEAL 2 Protocol
T2020-003 IDEAL 2 Sample Consent
Adverse Events
Correlative Studies
Data Safety Monitoring & Progress Reports
Roadmaps and Weekly Reports
Enrollment and Fitbit Ordering
eCRF Completion Guide
PedsQL
FAQ